tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shuttle Pharmaceuticals Advances Prostate Cancer Diagnostics Funding

Shuttle Pharmaceuticals Advances Prostate Cancer Diagnostics Funding

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shuttle Pharmaceuticals Holdings, Inc. has entered into an agreement with SRO, LLC to sell $2,250,000 worth of units, which include shares, warrants, and an equity interest in its subsidiary. This is part of a larger effort to raise $4,500,000 through a rights offering to existing stockholders, with SRO LLC providing a backstop to purchase any remaining units. The funds are intended to develop a diagnostics lab for FDA approval of a diagnostic metabolite panel for prostate cancer. The company also signed an agreement with Boustead Securities, LLC for financial and placement agent services for the rights offering.

For further insights into SHPH stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1